2026 Frost & Sullivan Summit – Life Science New Investment Forum is approaching!

Host City: Shanghai, China

Date: August 4-5, 2026

Conference Scale: 5,000+

Conference Format: Offline + Online Live Streaming

Organizer: Frost & Sullivan

●High-Level Forum on New Investments in Life Sciences (Parallel Session) – Biomedicine Track

Hot Terrain, Innovative Voyage

All day on August 5

As the industry cycle shifts from capital frenzy to rational development, China’s biopharmaceutical industry uses innovation as its weapon and globalization as its shield, establishing a new direction in value reconstruction. Immunotherapy has gone beyond the single success of CAR-T to make deep breakthroughs in multiple technologies such as TCR-T and CAR-NK. Advances in solid tumor treatment and general products indicate that cell therapy enters a new era of “multi-arms collaboration”.ADC、RDC and gene drugs are advancing in multiple fields. Global expansion has evolved from a vision into a strategic restructuring. This is not just a simple technological iteration, but a crucial leap for Chinese innovative drugs from “following” to “leading”. On this promising ground, Zhizhou has set sail.

●Life Science New Investment Summit Forum (Parallel Event) – Medical Devices Session

Innovation knows no bounds, medical devices achieve great things

All day on August 5

When intelligent technology integrates with other fields, breaking traditional boundaries, medical devices are transitioning from single manufacturing to an ecosystem. AI image recognition and intraoperative decision-making are no longer just auxiliary tools, but new engines for reshaping the healthcare value chain. The overseas strategy has undergone a qualitative change from product export to value chain restructuring. Under the new normal of centralized procurement, commercialization logic is redefining growth trends through “breakthroughs” rather than “adaptation”. Medical devices achieve great things because they become key variables in reconstructing medical costs and accessibility.

●Life Science New Investment Summit Forum (Parallel Event) – Health Technology Session

Zhizhi Life, reshaping health

All day on August 5

Health technology is experiencing a fundamental paradigm shift: from fragmented technical breakthroughs to systematic intervention throughout the life cycle. The core feature of the current landscape is the deep integration of data, algorithms, and biotechnology—AI is no longer an auxiliary tool, but a new engine driving target discovery and efficacy prediction. As engineered cell technology breaks through the traditional medical limitation of “only repairable, difficult to rebuild”, health technology will move from “curing diseases” to “shaping life”, extending from functional recovery to the unity of aesthetics and quality of life. A more systematic and predictive future for health is being written together by today’s technology integrators and ecosystem builders.

The SULLIVAN Growth, Innovation and Leadership Best Practices Award (abbreviated as GIL Awards) aims to recognize outstanding companies that have made significant contributions and achieved leadership positions in various industries. After nearly 30 years of development worldwide, the authority and fairness of this award have been widely recognized by the investment and financial communities, as well as within the industry. To date, over 5,000 excellent companies have been honored globally.

2026 marks the 65th anniversary of Frost & Sullivan’s establishment. Frost & Sullivan China will continue to track numerous entrepreneurial and investment success cases in high-tech and strategic emerging industries throughout 2026. It will conduct objective analysis and comprehensive evaluation of the innovation capabilities, business models, founding teams, technical abilities, and future prospects of the participating companies, and jointly select several outstanding biotech leading enterprises with a professional judging committee. The winners of the 2026 GIL Awards will be announced during this conferenceAt the 65th Anniversary Celebration of Frost & Sullivan’s Establishment and the 20th Anniversary Celebration of Frost & Sullivan Summit in ChinaNow announced.

At this conference, Frost & Sullivan will release seven blue books, coveringHong Kong 18A, biopharmaceutical internationalization, gene therapy, brain-computer interface, digital medical imaging, synthetic biology andanimal-derived collagenother cutting-edge sectors, focusing on the forefront of global technological changes and industrial restructuring, and providing in-depth insights into innovation trends and investment directions in the life sciences field.

‘2026 Hong Kong 18A Biotech Industry Development Blue Book’ English and Chinese Version

With the acceleration of global innovative drug research and development, the continuous improvement of Hong Kong Stock Exchange’s capital market systems, and multiple factors in China’s biopharmaceutical industry transformation and upgrading, the Hong Kong 18A rules have gone through pilot exploration and entered a mature development phase of standardization and normalization. The reform of China’s biopharmaceutical capital market is being implemented in depth. As a special listing channel for unprofitable biotech companies, the 18A system breaks down the barriers between innovation research and development and the capital market, helping domestic pharmaceutical companies achieve full-chain breakthroughs from clinical development to industrialization.

Under this background, Frost & Sullivan has integrated vast data such as the global biotech secondary market conditions, investment and financing in primary and secondary markets, and IPO issuance transactions to compile this blue book: reviewing the ten-year cycle changes in the global biopharmaceutical capital market and the evolution path of 18A policies vertically, analyzing the 18A industry landscape, popular innovation sectors, and the core fundamentals of listed companies horizontally; fromPre-IPOfinancing, new share issuance to post-IPO secondary market performance, quantitative analysis of valuation and operating data across the entire chain; combining with Hong Kong’sRWAasset tokenization innovation model to explore diversified new financing models for biopharmaceuticals, and including annual IPO agents, listed companies, institutional investments and other authoritative rankings. It also provides in-depth analysis of growth prospects, corporate pipeline value, and commercialization potential in various sectors, offering quantitative data, industry insights, and decision-making basis for enterprise services, consumer electronics, cross-border e-commerce trade, building technology, construction & decoration, beauty & fashion, smart homes, digital infrastructure, enterprise services, consumer electronics, and public sector.

[Collaborative Blue Book]

Please scan the QR code below, and we will contact you!

‘2026 China Biopharmaceutical Internationalization Development Blue Book’ English and Chinese Version

China biopharmaceutical companies’ “internationalization” is an inevitable choice for the Chinese innovative drug industry to actively participate in global industrial division of labor and seek larger market space and higher value realization paths after completing early capacity accumulation. In the past, Chinese biopharmaceutical companies relied more on local clinical resources, engineer advantages, and rapid iteration capabilities to start innovation. However, as local market competition intensifies, payment constraints increase, and homogeneous pipelines grow, internationalization becomes an important direction for companies to break through growth boundaries, verify innovation value, and enhance capital recognition. Meanwhile, global pharmaceutical companies are re-evaluating Chinese innovation capabilities, considering Chinese companies as important research cooperation partners, asset sources, and industrial chain partners. Based on this, Frost & Sullivan releases the ‘2026 China Biopharmaceutical Internationalization Development Blue Book’ to systematically outline the stage characteristics, driving factors, main paths, and future trends of China’s biopharmaceutical companies’ internationalization, and discuss with industry participants, investors, and stakeholders the long-term value and development blueprint of China’s biopharmaceutical industry in global markets.

[Collaborative Blue Book]

Please scan the QR code below, and we will contact you!

English and Chinese Version of '2026 Global Gene Therapy Industry Development Blue Book'"

Driven by continuous technological breakthroughs, improved regulatory frameworks, and increased capital investment, the gene therapy industry is rapidly moving from an early technical exploration stage to commercialization. Notably, China’s 15th Five-Year Plan has included biomanufacturing as one of the core directions of strategic emerging industries, and gene therapy has been identified as a key area requiring “significant progress.” Under the 15th Five-Year macro-strategy, gene therapy is no longer merely a market activity driven by technology exploration and capital, but has become a crucial component in building national biological economic competitiveness. It requires systematic improvements in carrier technology, production process upgrades, clinical translation efficiency, and regulatory system enhancements. However, the industry still faces systemic challenges such as complex production processes, insufficient scale production capacity, high shell rate, high costs, long-term data validation, and an imperfect payment system. In this context, Frost & Sullivan aims to provide a comprehensive analysis of the development stages, technical systems, and industrial chain structures of the gene therapy industry through this blue book, including an in-depth examination of key technological barriers, commercialization paths, and market opportunities, offering forward-looking market insights and strategic decision-making references for all industry participants.

[Participation Cooperation Blue Book]

Please scan the QR code below, and we will contact you!

English and Chinese Version of '2026 Global Brain-Computer Interface Industry Development White Paper'"

Currently, innovative achievements in the field of brain-computer interfaces in China are emerging continuously, and the industry is developing rapidly, becoming an important area for the deep integration of technological innovation and industrial innovation. By establishing a full-chain ecosystem of “technical research—application scenarios—industrial clustering” and prioritizing review mechanisms, China is accelerating its transition from key technology breakthroughs to global industry leadership, creating new advantages for Chinese enterprises in international competition. In this context, Frost & Sullivan aims to provide a comprehensive analysis of the development stages, structural characteristics, and evolution paths of the industry, including an in-depth examination of key application areas and market opportunities, offering forward-looking market insights and strategic decision-making references for all industry participants to seize opportunities and address challenges.

[Participation Cooperation Blue Book]

Please scan the QR code below, and we will contact you!

English and Chinese Version of '2026 Global Digital Intelligence Medical Imaging Ecosystem Industry Development Blue Book'"

As artificial intelligence reshapes countless industries at an unprecedented pace, the healthcare sector is undergoing a profound transformation from “experience-driven” to “data intelligence.” In this transformation, AI medical imaging is undoubtedly one of the most highly focused and clinically valuable sectors. However, this integration is triggering deeper changes: AI is no longer just the “second pair of eyes” for radiologists, but has become a decisive factor in driving the digital intelligence evolution of the medical imaging ecosystem. Starting from the current construction status and pain points of the medical imaging ecosystem, we will analyze how medical imaging AI can empower the ecosystem in the era of AGI, and then envision the future development of the digital intelligence imaging ecosystem. Through this blue book, we hope to enable the public to better understand the development of the medical imaging ecosystem and how AI medical imaging can truly become a partner and digital replica in doctors’ diagnostic processes.

English and Chinese Version of '2026 Global Synthetic Biology Industry Development White Paper'"

Synthetic biology is widely defined by academia and industry as the third life sciences revolution following the discovery of the DNA double helix structure and the genomic technology revolution. The 2026 Government Work Report clearly states the need to foster and strengthen emerging and future industries, and promote biomanufacturing as a new economic growth point. Synthetic biology and biomanufacturing are no longer just technical issues, but a triple intersection of national security (independent supply chain control), climate agenda (Dual Carbon/Zero-Carbon Negative Carbon), and economic growth (new quality productive forces). Based on long-term insights into global cutting-edge technology and biomanufacturing industries, Frost & Sullivan has launched the '2026 Global Synthetic Biology Industry Development Blue Book', providing a comprehensive industry perspective through an industrial chain panorama, country/region comparisons, and in-depth analysis of regulatory-technological-commercial dimensions, offering a holistic view of industry trends.

[Participation Cooperation Blue Book]

Please scan the QR code below, and we will contact you!

English and Chinese Version of '2026 Global Animal-derived Collagen Product Development White Paper'"

With the continuous development of regenerative medicine, medical aesthetics, and biomaterials industries, animal-derived collagen benefits from its natural and complete three-helix structure, excellent biological activity, and long-term clinical application validation, expanding its applications in tissue repair, high-end medical devices, regenerative medicine, and medical aesthetics. Continuous breakthroughs in key technologies such as extraction and purification, and self-assembly, further enhance the functional value of animal-derived collagen and drive the industry toward higher-end and specialized development. As a global important collagen production and consumption market, China is promoting high-quality industry development driven by technological innovation, industrial upgrading, and expanded application scenarios.

In this context, Frost & Sullivan, in collaboration with Fierce Biotech, provides a comprehensive analysis of the current development status, technological evolution, industrial chain ecology, market size, competitive landscape, policy environment, and future development trends of the global and Chinese animal-derived collagen industry, which is important for understanding industry development.

Life Sciences New Investment Summit

Event Consultation | Sponsorship Cooperation | Participation Inquiry

📞 Conference Consultation Hotline:

021-3209-6800 ext. 8672

📧 Conference Consultation Email:

gil@frostchina.com